Sanofi Ambien patent
Sanofi will list Ambien patent covering modified-release version of insomnia agent in FDA's "Orange Book," company says. Patent for zolpidem MR (no. 6,514,531) would run to 2019; Ambien exclusivity currently expires in 2006. Sanofi plans to file in 2004 for FDA approval (1"The Pink Sheet" Feb. 24, p. 15)...
You may also be interested in...
Sanofi-Synthelabo plans to file for approval of a modified-release formulation of the insomnia agent Ambien during the second quarter of 2004
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.